Compare OneSpan Inc (OSPN) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs TransMedics Group Inc — how do they compare? OneSpan Inc trades at $16.12 (market cap $593.32M), while TransMedics Group Inc trades at $85.89 (market cap $3.06B). The key difference: TransMedics Group Inc is far larger — about 5.2× OneSpan Inc's market cap, and OneSpan Inc pays a 3.23% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| OSPN | TMDX | |
|---|---|---|
Market Cap | $593.32M | $3.06B |
Sector | Technology | Technology |
52-Week High | $16.92 | $150.42 |
52-Week Low | $10.15 | $61.99 |
Enterprise Value | $562.40M | $3.46B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $16.1, down 3.59% on the day, with technical indicators showing a neutral trend and key support at $16. The stock exhibits strong fundamentals, including a P/E of 9.1, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights institutional interest, such as Deutsche Bank's new position, and the company's introduction of DigipassONE for authentication modernization.
The outlook for OSPN is positive, supported by solid financials and analyst consensus, but risks include competitive pressures and cash flow volatility. With a consensus price target of $17.00 and 66.67% buy ratings, the stock offers potential upside, though investors should monitor execution risks and market sentiment shifts.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
